WO1997004748B1 - Enveloppes virales artificielles renforcees pour l'apport de substances therapeutiques dans les cellules - Google Patents
Enveloppes virales artificielles renforcees pour l'apport de substances therapeutiques dans les cellulesInfo
- Publication number
- WO1997004748B1 WO1997004748B1 PCT/US1996/012750 US9612750W WO9704748B1 WO 1997004748 B1 WO1997004748 B1 WO 1997004748B1 US 9612750 W US9612750 W US 9612750W WO 9704748 B1 WO9704748 B1 WO 9704748B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- liposome
- polynucleotide
- component
- bifunctional
- tissue targeting
- Prior art date
Links
- 239000000126 substance Substances 0.000 title claims abstract 7
- 210000004779 membrane envelope Anatomy 0.000 title claims abstract 4
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 230000001413 cellular effect Effects 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 claims abstract 23
- 102000040430 polynucleotide Human genes 0.000 claims abstract 23
- 239000002157 polynucleotide Substances 0.000 claims abstract 23
- 150000002632 lipids Chemical class 0.000 claims abstract 18
- 230000008685 targeting Effects 0.000 claims abstract 13
- 210000004027 cell Anatomy 0.000 claims abstract 11
- 230000000799 fusogenic effect Effects 0.000 claims abstract 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 8
- 238000001415 gene therapy Methods 0.000 claims abstract 4
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 4
- 108090000623 proteins and genes Proteins 0.000 claims abstract 4
- 102000004169 proteins and genes Human genes 0.000 claims abstract 4
- 239000002502 liposome Substances 0.000 claims 26
- 238000000034 method Methods 0.000 claims 14
- 230000001588 bifunctional effect Effects 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 5
- 239000003599 detergent Substances 0.000 claims 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 210000002889 endothelial cell Anatomy 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229940076279 serotonin Drugs 0.000 claims 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- -1 anionic lipid Chemical class 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 239000002753 trypsin inhibitor Substances 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 230000006835 compression Effects 0.000 abstract 1
- 238000007906 compression Methods 0.000 abstract 1
- 238000005538 encapsulation Methods 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
Abstract
La présente invention concerne des enveloppes virales artificielles et d'autres vésicules lipidiques qui encapsulent des substances thérapeutiques telles que des vecteurs d'expression visant des cellules de mammifères. Les polynucléotides peuvent être mis dans les enveloppes par compression à l'avance avec un peptide court ayant une charge positive prédominante. L'opération de compression non seulement facilite l'encapsulation mais elle augmente aussi le nombre de vésicules contenant de l'acide nucléique, réduit au minimum la quantité d'acide nucléique libre, et elle peut aussi augmenter la taille et la complexité des plasmides qui peuvent être encapsulés. Les vésicules peuvent être pourvues d'un constituant ciblant des tissus, qui aide à les diriger vers certains sites tissulaires d'un animal, et elles peuvent aussi être pourvues d'un constituant fusogénique qui facilite l'apport de la substance thérapeutique dans la cellule. Les substances et les réactifs selon la présente invention sont efficaces, par exemple, pour accroître l'expression de protéines modèles à la fois dans des cellules isolées et chez des animaux intacts, et on s'attend à ce qu'ils soient utiles pour la thérapie génique.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU66914/96A AU6691496A (en) | 1995-08-01 | 1996-08-01 | Enhanced artificial viral envelopes for cellular delivery of therapeutic substances |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US173895P | 1995-08-01 | 1995-08-01 | |
| US60/001,738 | 1995-08-01 | ||
| US258095P | 1995-08-21 | 1995-08-21 | |
| US60/002,580 | 1995-08-21 | ||
| US69061396A | 1996-07-31 | 1996-07-31 | |
| US60/690,613 | 1996-07-31 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| WO1997004748A2 WO1997004748A2 (fr) | 1997-02-13 |
| WO1997004748A3 WO1997004748A3 (fr) | 1997-05-29 |
| WO1997004748B1 true WO1997004748B1 (fr) | 1997-07-17 |
| WO1997004748A9 WO1997004748A9 (fr) | 1997-10-09 |
Family
ID=27356985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1996/012750 WO1997004748A2 (fr) | 1995-08-01 | 1996-08-01 | Enveloppes virales artificielles renforcees pour l'apport de substances therapeutiques dans les cellules |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU6691496A (fr) |
| WO (1) | WO1997004748A2 (fr) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6008202A (en) | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US6258792B1 (en) | 1996-04-12 | 2001-07-10 | University Of Pittsburgh | Cationic cholesteryl derivatives containing cyclic polar groups |
| CA2251543A1 (fr) * | 1996-04-12 | 1997-10-23 | University Of Pittsburgh | Nouveaux derives de cholesteryle cationiques contenant des groupes polaires cycliques |
| FR2751222B1 (fr) * | 1996-07-16 | 1998-10-09 | Capsulis | Compositions contenant au moins un acide nucleique et leurs applications dans le domaine biomedical, en particulier en therapie genique |
| TWI225412B (en) * | 1997-06-23 | 2004-12-21 | Sequus Pharm Inc | Liposome-entrapped polynucleotide composition and method |
| DE69838521T2 (de) | 1997-07-07 | 2008-05-21 | Medical Research Council | Methode zur Erhöhung der Konzentration von Nucleinsäuremolekülen |
| FR2766705B1 (fr) * | 1997-07-30 | 2001-05-25 | Biovector Therapeutics | Complexe particulaire de charge globale neutre ou negative forme d'une vesicule cationique ou neutre et d'une substance biologiquement active anionique, leur preparation et leur utilisation |
| FR2766706B1 (fr) * | 1997-07-30 | 2001-05-25 | Biovector Therapeutics Sa | Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation |
| US6372720B1 (en) * | 1998-02-05 | 2002-04-16 | Kenneth J. Longmuir | Liposome fusion and delivery vehicle |
| US6903196B1 (en) | 1999-06-17 | 2005-06-07 | Utah Ventures Ii, L.P. | Methods for identifying and isolating tissue-specific lumen-exposed molecules |
| US20030021792A1 (en) * | 2001-06-08 | 2003-01-30 | Roben Paul W. | Tissue-specific endothelial membrane proteins |
| GB0015624D0 (en) * | 2000-06-26 | 2000-08-16 | Nat Cancer Centre | Materials and methods relating to improved gene delivery |
| WO2002041870A2 (fr) * | 2000-11-22 | 2002-05-30 | Vectron Therapeutics Ag | Production et utilisation d'un systeme de diagnostic cible |
| WO2002042468A2 (fr) | 2000-11-27 | 2002-05-30 | Geron Corporation | Vecteurs de glycosyltransferase pour traitement du cancer |
| EP2228387A2 (fr) * | 2001-04-18 | 2010-09-15 | The Open University | Polypeptides dérivés de l'APP (Protéine Précurseur Amyloide), et leurs utilisations |
| US7622446B2 (en) | 2001-04-18 | 2009-11-24 | The Open University | Polypeptides, derivatives and uses thereof |
| US7491702B2 (en) | 2001-04-18 | 2009-02-17 | The Open University | Polypeptides related to amyloid precursor protein, pharmaceutical compositions thereof, and methods of treatment using the same |
| AU2002256398A2 (en) * | 2001-04-30 | 2002-11-11 | Targeted Genetics Corporation | Lipid-comprising drug delivery complexes and methods for their production |
| EP1568379A1 (fr) * | 2002-11-01 | 2005-08-31 | Genomidea Inc | Preparation medicinale comprenant un agent chimiotherapeutique encapsule |
| US20060078893A1 (en) | 2004-10-12 | 2006-04-13 | Medical Research Council | Compartmentalised combinatorial chemistry by microfluidic control |
| GB0307428D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Compartmentalised combinatorial chemistry |
| GB0307403D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Selection by compartmentalised screening |
| US20050221339A1 (en) | 2004-03-31 | 2005-10-06 | Medical Research Council Harvard University | Compartmentalised screening by microfluidic control |
| US7968287B2 (en) | 2004-10-08 | 2011-06-28 | Medical Research Council Harvard University | In vitro evolution in microfluidic systems |
| BRPI0608927B1 (pt) | 2005-03-23 | 2021-11-23 | Genmab A/S | Anticorpo que se liga a cd38 humano, vetor de expressão, célula hospedeira procariótica, imunoconjugado, molécula bi-específica ou multi-específica, composição farmacêutica, uso de um anticorpo, de um imunoconjugado, de uma composição farmacêutica e de um vetor de expressão, método in vitro para detectar a presença de antígeno de cd38, ou uma célula que expresse cd38, em uma amostra, e, kit |
| WO2007081387A1 (fr) | 2006-01-11 | 2007-07-19 | Raindance Technologies, Inc. | Dispositifs microfluidiques, méthodes d'utilisation, et trousses permettant de faire des diagnostics |
| US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
| EP2047910B1 (fr) | 2006-05-11 | 2012-01-11 | Raindance Technologies, Inc. | Dispositif microfluidique et procédé |
| US9012390B2 (en) | 2006-08-07 | 2015-04-21 | Raindance Technologies, Inc. | Fluorocarbon emulsion stabilizing surfactants |
| WO2008097559A2 (fr) | 2007-02-06 | 2008-08-14 | Brandeis University | Manipulation de fluides et de réactions dans des systèmes microfluidiques |
| US8592221B2 (en) | 2007-04-19 | 2013-11-26 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
| PL2612868T3 (pl) | 2007-11-01 | 2018-12-31 | Astellas Pharma Inc. | Immunosupresyjne polipeptydy i kwasy nukleinowe |
| WO2010009365A1 (fr) | 2008-07-18 | 2010-01-21 | Raindance Technologies, Inc. | Bibliothèque de gouttelettes |
| US12038438B2 (en) | 2008-07-18 | 2024-07-16 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
| EP3415235A1 (fr) | 2009-03-23 | 2018-12-19 | Raindance Technologies Inc. | Manipulation de gouttelettes microfluidiques |
| EP2486409A1 (fr) | 2009-10-09 | 2012-08-15 | Universite De Strasbourg | Nanomatériau marqué à base de silice à propriétés améliorées et ses utilisations |
| WO2011079176A2 (fr) | 2009-12-23 | 2011-06-30 | Raindance Technologies, Inc. | Systèmes microfluidiques et procédés pour réduire l'échange de molécules entre des gouttelettes |
| US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
| US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
| EP4484577A3 (fr) | 2010-02-12 | 2025-03-26 | Bio-Rad Laboratories, Inc. | Analyse numérique d'analyte |
| US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
| EP3447155A1 (fr) | 2010-09-30 | 2019-02-27 | Raindance Technologies, Inc. | Dosages en sandwich dans des gouttelettes |
| EP3859011A1 (fr) | 2011-02-11 | 2021-08-04 | Bio-Rad Laboratories, Inc. | Procédés permettant de former des gouttelettes mélangées |
| WO2012112804A1 (fr) | 2011-02-18 | 2012-08-23 | Raindance Technoligies, Inc. | Compositions et méthodes de marquage moléculaire |
| US9556470B2 (en) | 2011-06-02 | 2017-01-31 | Raindance Technologies, Inc. | Enzyme quantification |
| US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
| US8658430B2 (en) | 2011-07-20 | 2014-02-25 | Raindance Technologies, Inc. | Manipulating droplet size |
| WO2013142514A1 (fr) * | 2012-03-19 | 2013-09-26 | Isis Pharmaceuticals, Inc. | Procédés et compositions destinés à la modulation de l'expression de l'alpha-1-antitrypsine |
| US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
| US9944977B2 (en) | 2013-12-12 | 2018-04-17 | Raindance Technologies, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
| EP3090063B1 (fr) | 2013-12-31 | 2019-11-06 | Bio-Rad Laboratories, Inc. | Procédé de détection de rétrovirus latent |
| US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
| AU2019269593A1 (en) * | 2018-05-15 | 2020-11-26 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2958076B2 (ja) * | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| PL296382A1 (en) * | 1991-02-02 | 1993-11-02 | Nika Health Products Ltd Li Li | Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system |
| DE4139001A1 (de) * | 1991-11-27 | 1993-06-03 | Boehringer Mannheim Gmbh | Verfahren zur einschleusung von nukleinsaeuren in zellen |
| WO1994018947A1 (fr) * | 1993-02-16 | 1994-09-01 | Sharifa Karali | Complexe protamine-adn de haute purete et son utilisation |
| EP1489184A1 (fr) * | 1995-06-07 | 2004-12-22 | Inex Pharmaceutical Corp. | Particules d'acides nucléiques et de lipides préparées au moyen d'un intermédiaire de complexe hydrophobe d'acides nucléiques et de lipides et utilisation pour transférer des gènes |
-
1996
- 1996-08-01 AU AU66914/96A patent/AU6691496A/en not_active Abandoned
- 1996-08-01 WO PCT/US1996/012750 patent/WO1997004748A2/fr active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1997004748B1 (fr) | Enveloppes virales artificielles renforcees pour l'apport de substances therapeutiques dans les cellules | |
| WO1997004748A3 (fr) | Enveloppes virales artificielles renforcees pour l'apport de substances therapeutiques dans les cellules | |
| US5766625A (en) | Artificial viral envelopes | |
| US5567433A (en) | Liposome preparation and material encapsulation method | |
| US5100662A (en) | Steroidal liposomes exhibiting enhanced stability | |
| KR100507660B1 (ko) | 리포좀 | |
| AU631377B2 (en) | Affinity associated vaccine | |
| US4663161A (en) | Liposome methods and compositions | |
| US5252348A (en) | Artificial viral envelopes | |
| US6040167A (en) | Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems | |
| JPH07126185A (ja) | オリゴ糖を表面に有するリポソーム | |
| WO1997000965A2 (fr) | Vecteur lipidique servant a l'administration d'acides nucleiques | |
| Frisch et al. | Parameters affecting the immunogenicity of a liposome‐associated synthetic hexapeptide antigen | |
| JP2001523216A (ja) | 新規のアジュバント組成物と、それからなるワクチン製剤 | |
| EP0356340B1 (fr) | Vaccin à affinité associée | |
| Tikchonenko et al. | Transfer of condensed viral DNA into eukaryotic cells using proteoliposomes | |
| US5897873A (en) | Affinity associated vaccine | |
| EP1190255B1 (fr) | Epitopes formes par association non covalente de conjugues | |
| US20090136563A1 (en) | Method for Coating Particle with Lipid Film | |
| EP0525163B1 (fr) | Liaison d'une hormone de croissance aux liposomes | |
| WO1990001947A1 (fr) | Vaccin a affinite associee | |
| EP0555333B1 (fr) | Enveloppes virales artificielles | |
| EP0202017B1 (fr) | Structures microcellulaires artificielles et leur procédé de fabrication | |
| JP2002538196A5 (fr) | ||
| Beatty et al. | Liposome stimulation of anti-BSA antibody production in mice |